支气管哮喘患者血清IP-10水平及吸入沙美特罗替卡松对其影响的研究  

IP-10 levels in asthmatic patients and changes after salmeteroi and fluticasone propionate powder inhalation

作　　者：谢强[1] 邓静敏[1] 邹小英[1] 韦旋[1] 

机构地区：[1]广西医科大学第一附属医院呼吸内科,南宁530021

出　　处：《国际呼吸杂志》2011年第9期659-662,共4页International Journal of Respiration

基　　金：基金项目：广西科学基金项目（桂科青0991028）

摘　　要：目的通过观测支气管哮喘（简称哮喘）患者与正常人的血清干扰素诱导蛋白-10（IP-10）水平以及哮喘患者吸入沙美特罗替卡松后血清IP-10的变化情况，初步探讨IP-10在哮喘发病机制中的作用。方法16例哮喘患者分别于治疗前及吸人沙美特罗替卡松治疗30d后检测肺功能、抽取静脉血测定IP-10、INF-γ（酶联免疫吸附试验法）及外周血嗜酸粒细胞、淋巴细胞计数，并进行比较；8例健康体检者仅抽取静脉血测定IP-10、INF-7水平并与哮喘组相比较。结果哮喘组血清IP-10水平高于正常组（P〈0．05）而INF-γ水平低于正常组（P〈0．01），治疗1个月后前者明显下降（P〈0．05）而后者显著升高（P〈0．01），并与正常组水平差异无统计学意义（P〉0．05）；哮喘组治疗1个月后FEV1％pred、PEF％pred较治疗前升高（P〈0．01），嗜酸粒细胞计数均较治疗前降低（P〈0．05）；血清IP-10水平与FEV1％pred水平呈中度负相关（P〈0．05）。结论IP-10参与了哮喘的发病，进一步提示哮喘发病机制的复杂性；哮喘患者吸入激素联合长效β2受体激动剂治疗后可显著降低血清IP-10水平。Objective To investigate interferon-inducible protein-10 （IP-10）＇s role in the pathogenesis of asthma we observed serum IP 10 levels in asthmatic patients and healthy persons, and examined the changes of serum IP-10 in asthmatic patients inhaled salmeterol and fluticasone propionate powder. Methods 16 asthmatic patients inhaled salmeterol and fluticasone propionate powder for a month were detected their lung functions, peripheral blood eosinophils and lymphocytes counts, and serum IP-10, INF-γ （using enzyme-linked immune assay）, then compared with each other. Eight healthy volunteers just measured serum IP-10, INF-γ and Compared with the asthma group. Results Serum IP-10 levels in asthmatic patients before treatment were significantly higher than healthy volunteers （ P 〈0.05） and serum INF-γ levels were significantly lower than healthy volunteers （ P 〈 0.01）. After 1 month treatment the levels of IP-10 decreased （ P 〈0.05） while INF-γ increased （ P 〈0.01） ,and there were no significant difference between asthmatic patients and healthy volunteers （ P 〉 0.05）. After treatment, the FEV1 % pred and PEF% pred of asthmatic patients increased （ P 〈0.01） ,while the eosinophils counts decreased （ P 〈0.05）. Serum IP-10 levels correlated negatively with FEV1 % pred for asthmatic patients （ P 〈0.05）. Conclusions IP-10 may be involved in the pathogenesis of asthma and further indicated the complexity of the pathogenesis of asthma. Treatment with inhaled glucocorticosteroids and long-acting inhaled β2 agonists can significantly reduce serum IP-10 level in asthma.

关 键 词：哮喘 干扰素诱导蛋白-10 7干扰素 吸入治疗 

分 类 号：R562.25[医药卫生—呼吸系统]